<?xml version="1.0" encoding="UTF-8"?>
<p>Last, the incorporation of new molecular targeted drugs into the current standard regimens is an attractive approach to improving the efficacy of treatment strategies for MCL patients. It has been reported that Bruton's tyrosine kinase inhibitors and phosphoinositide 3‐kinase inhibitors showed high efficacy in relapsed or refractory MCL patients.
 <xref rid="cas13719-bib-0025" ref-type="ref">25</xref> Further improvements of our regimen, including more efficient harvest of auto‐PBSC and/or incorporation of promising new molecular targeting agents, are important future goals.
</p>
